(FATE) Fate Therapeutics - NASDAQ

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 228m USD | Total Return: 75.6% in 12m

NK Cells, T-Cells, Immunotherapies, Cancer Treatments, Autoimmune Therapies
Total Rating 42
Safety 36
Buy Signal 0.29
Biotechnology
Industry Rotation: +7.9
Market Cap: 228M
Avg Turnover: 7.89M
Risk 3d forecast
Volatility96.4%
VaR 5th Pctl15.1%
VaR vs Median-5.19%
Reward TTM
Sharpe Ratio0.99
Rel. Str. IBD95
Rel. Str. Peer Group83
Character TTM
Beta1.798
Beta Downside1.628
Hurst Exponent0.553
Drawdowns 3y
Max DD91.86%
CAGR/Max DD-0.28
CAGR/Mean DD-0.40
EPS (Earnings per Share) EPS (Earnings per Share) of FATE over the last years for every Quarter: "2021-06": -0.58, "2021-09": -0.45, "2021-12": -0.72, "2022-03": -0.68, "2022-06": -0.78, "2022-09": -0.86, "2022-12": -0.58, "2023-03": -0.19, "2023-06": -0.54, "2023-09": -0.46, "2023-12": -0.45, "2024-03": -0.47, "2024-06": -0.33, "2024-09": -0.4, "2024-12": -0.44, "2025-03": -0.32, "2025-06": -0.29, "2025-09": -0.27, "2025-12": -0.27, "2026-03": -0.26,
Last SUE: 0.42
Qual. Beats: 0
Revenue Revenue of FATE over the last years for every Quarter: 2021-06: 13.412, 2021-09: 14.225, 2021-12: 17.069, 2022-03: 18.414, 2022-06: 18.549, 2022-09: 14.981, 2022-12: 44.356, 2023-03: 58.98, 2023-06: 0.933, 2023-09: 1.944, 2023-12: 1.676, 2024-03: 1.925, 2024-06: 6.772, 2024-09: 3.074, 2024-12: 1.86, 2025-03: 1.629, 2025-06: 1.907, 2025-09: 1.741, 2025-12: 1.369, 2026-03: 1.299,
Rev. CAGR: -62.94%
Rev. Trend: -81.8%
Last SUE: -0.14
Qual. Beats: 0

Warnings

Altman Z'' -15.00 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

Rs Leader, Idiosyncratic Leader

Description: FATE Fate Therapeutics

Fate Therapeutics, Inc. (FATE) is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and autoimmune disorders. The company utilizes a proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf NK and T-cell product candidates, such as FT522 and FT819, aimed at treating B-cell lymphoma and systemic lupus erythematosus. This iPSC-based approach is designed to eliminate the need for patient-sourced cells, potentially reducing manufacturing costs and increasing treatment scalability compared to traditional autologous CAR-T therapies.

The company operates within the biotechnology sector, where high research and development expenses are standard before achieving commercial viability. Fate maintains a strategic collaboration with Ono Pharmaceutical Co. Ltd. to co-develop CAR T-cell therapies specifically targeting solid tumors. Investors may find ValueRays quantitative tools useful for evaluating the long-term risk profile of clinical-stage biotech firms. Headquartered in San Diego, Fate Therapeutics continues to advance its pipeline from preclinical stages through human clinical trials.

Headlines to Watch Out For
  • Clinical trial data readouts for iPSC-derived CAR T-cell therapies drive valuation
  • Expansion into autoimmune indications like lupus dictates long-term market opportunity
  • Strategic collaboration revenue and milestone payments from Ono Pharmaceutical impact cash runway
  • High research and development expenses necessitate future dilutive capital raises
  • FDA regulatory pathways for off-the-shelf cellular immunotherapies influence commercialization timelines
Piotroski VR-10 (Strict) 0.0
Net Income: -129.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.36 > 0.02 and ΔFCF/TA -5.01 > 1.0
NWC/Revenue: 2.36k% < 20% (prev 1.65k%; Δ 706.3% < -1%)
CFO/TA -0.36 > 3% & CFO -103.1m > Net Income -129.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.85 > 1.5 & < 3
Outstanding Shares: last quarter (120.0m) vs 12m ago 1.40% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 1.85% > 50% (prev 3.34%; Δ -1.50% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.52 (Total Current Assets 179.5m - Total Current Liabilities 30.7m) / Total Assets 284.9m
B: -5.49 (Retained Earnings -1.57b / Total Assets 284.9m)
C: -0.38 (EBIT TTM -129.9m / Avg Total Assets 341.8m)
D: 1.71 (Book Value of Equity 179.7m / Total Liabilities 105.2m)
Altman-Z'' = -15.25 = D
Beneish M -4.00
DSRI: 0.62 (Receivables 704k/2.41m, Revenue 6.32m/13.3m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.33 (AQ_t 0.04 / AQ_t-1 0.11)
SGI: 0.47 (Revenue 6.32m / 13.3m)
TATA: -0.09 (NI -129.9m - CFO -103.1m) / TA 284.9m)
Beneish M = -4.12 (Cap -4..+1) = AAA
What is the price of FATE shares?

As of June 21, 2026, the stock is trading at USD 2.09 with a total of 4,122,848 shares traded.
Over the past week, the price has changed by +6.09%, over one month by +10.58%, over three months by +93.52% and over the past year by +75.63%.

Is FATE a buy, sell or hold?

Fate Therapeutics has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy FATE.

  • StrongBuy: 5
  • Buy: 1
  • Hold: 6
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the FATE price?
Analysts Target Price 5.4 158.9%
Fate Therapeutics (FATE) - Fundamental Data Overview as of 18 June 2026
Market Cap USD = 228.5m (228.5m USD * 1.0 USD.USD)
P/S = 36.171
P/B = 1.2259
Revenue TTM = 6.32m USD
EBIT TTM = -129.9m USD
EBITDA TTM = -117.4m USD
Long Term Debt = 72.0m USD (estimated: total debt 76.8m - short term 4.74m)
Short Term Debt = 4.74m USD (from shortTermDebt, last quarter)
Debt = 76.8m USD (from shortLongTermDebtTotal, last quarter) (leases 76.8m already included)
Net Debt = -98.0m USD (calculated: Debt 76.8m - CCE 174.8m)
Enterprise Value = 130.4m USD (228.5m + Debt 76.8m - CCE 174.8m)
 Interest Coverage Ratio = unknown (Ebit TTM -129.9m / Interest Expense TTM 0.0)
 EV/FCF = -1.28x (Enterprise Value 130.4m / FCF TTM -101.7m)
FCF Yield = -77.99% (FCF TTM -101.7m / Enterprise Value 130.4m)
 FCF Margin = -1.61k% (FCF TTM -101.7m / Revenue TTM 6.32m)
 Net Margin = -2.06k% (Net Income TTM -129.9m / Revenue TTM 6.32m)
 Gross Margin = unknown ((Revenue TTM 6.32m - Cost of Revenue TTM 35.6m) / Revenue TTM)
 Tobins Q-Ratio = 0.46 (Enterprise Value 130.4m / Total Assets 284.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 76.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -102.6m (EBIT -129.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.29 (Total Current Assets 179.5m / Total Current Liabilities 34.0m)
Debt / Equity = 0.43 (Debt 76.8m / totalStockholderEquity, last quarter 179.7m)
 Debt / EBITDA = 0.83 (negative EBITDA) (Net Debt -98.0m / EBITDA -117.4m)
 Debt / FCF = 0.96 (negative FCF - burning cash) (Net Debt -98.0m / FCF TTM -101.7m)
 Total Stockholder Equity = 220.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.01% (Net Income -129.9m / Total Assets 284.9m)
RoE = -58.89% (Net Income TTM -129.9m / Total Stockholder Equity 220.6m)
RoCE = -44.39% (EBIT -129.9m / Capital Employed (Equity 220.6m + L.T.Debt 72.0m))
 RoIC = -39.68% (negative operating profit) (NOPAT -102.6m / Invested Capital 258.7m)
 WACC = 9.21% (E(228.5m)/V(305.2m) * Re(12.31%) + D(76.8m)/V(305.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 9.13%
 [DCF] Fair Price = unknown (Cash Flow -101.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.42 | # QB: 0
Revenue Correlation: -81.75 | Revenue CAGR: -62.94% | SUE: -0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.26 | Chg30d=+0.62% | Revisions=+50% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.26 | Chg30d=-2.14% | Revisions=+56% | Analysts=9
EPS current Year (2026-12-31): EPS=-1.03 | Chg30d=-2.74% | Revisions=+60% | GrowthEPS=+10.2% | GrowthRev=-35.8%
EPS next Year (2027-12-31): EPS=-0.99 | Chg30d=-2.69% | Revisions=+25% | GrowthEPS=+4.2% | GrowthRev=+22.6%
[Analyst] Revisions Ratio: +60%